Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Deffered Revenue (2016 - 2025)

Regenxbio (RGNX) has 8 years of Non-Current Deffered Revenue data on record, last reported at $18.9 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $18.9 million; the TTM value through Dec 2025 reached $18.9 million, changed N/A, while the annual FY2025 figure was $18.9 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $18.9 million in Q4 2025 per RGNX's latest filing, down from $21.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $26.3 million in Q1 2025 and bottomed at $3.5 million in Q3 2021.